ECM
VRTX icon

ETrade Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

ETrade Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$2.26M Sell
8,294
-770
-8% -$212K 0.04% 208
2020
Q2 		$2.63M Sell
9,064
-107
-1% -$29K 0.05% 184
2020
Q1 		$2.18M Buy
9,171
+75
+0.8% +$17.2K 0.06% 182
2019
Q4 		$1.99M Sell
9,096
-378
-4% -$76.5K 0.04% 213
2019
Q3 		$1.6M Sell
9,474
-915
-9% -$162K 0.04% 242
2019
Q2 		$1.91M Buy
10,389
+291
+3% +$50.9K 0.05% 215
2019
Q1 		$1.86M Sell
10,098
-1,799
-15% -$332K 0.05% 215
2018
Q4 		$1.97M Buy
11,897
+65
+0.5% +$11.3K 0.06% 172
2018
Q3 		$2.28M Buy
11,832
+790
+7% +$141K 0.07% 173
2018
Q2 		$1.88M Buy
11,042
+603
+6% +$93.5K 0.06% 191
2018
Q1 		$1.7M Sell
10,439
-738
-7% -$121K 0.05% 208
2017
Q4 		$1.68M Buy
11,177
+1,874
+20% +$277K 0.05% 212
2017
Q3 		$1.41M Buy
9,303
+819
+10% +$123K 0.05% 223
2017
Q2 		$1.09M Buy
8,484
+1,596
+23% +$192K 0.04% 243
2017
Q1 		$753K Buy
6,888
+1,601
+30% +$141K 0.03% 348
2016
Q4 		$389K Buy
5,287
+1,636
+45% +$133K 0.02% 439
2016
Q3 		$318K Buy
3,651
+714
+24% +$67.5K 0.02% 442
2016
Q2 		$253K Buy
2,937
+401
+16% +$34.6K 0.01% 429
2016
Q1 		$202K Buy
2,536
+491
+24% +$44.4K 0.01% 442
2015
Q4 		$257K Buy
+2,045
New +$247K 0.02% 399
2013
Q4 		– Sell
-9
Closed -$1K – 915
2013
Q3 		$1K Buy
+9
New +$716 ﹤0.01% 900

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ETrade Capital Management's VRTX Position: Q3 2020 in Review

ETrade Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 8.5% in Q3 2020, selling an estimated $212K and leaving 8,294 shares worth $2.26M. The position accounts for 0.04% of the portfolio, ranked #208.

ETrade Capital Management first reported a position in VRTX in Q3 2013 and has held it in 21 quarters since. The position peaked at $2.63M in Q2 2020. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • ETrade Capital Management held 8,294 shares of Vertex Pharmaceuticals worth $2.26M as of Q3 2020.
  • ETrade Capital Management sold 770 Vertex Pharmaceuticals shares in Q3 2020, an estimated $212K.
  • Vertex Pharmaceuticals made up 0.04% of ETrade Capital Management's portfolio in Q3 2020, its #208 holding.
  • ETrade Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 21 quarters since.
  • ETrade Capital Management's Vertex Pharmaceuticals position peaked at $2.63M in Q2 2020.
  • 951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.